

Date: 13.08.2019

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai - 400 001

**Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 30, 33 of SEBI (LODR) Regulations, 2015.**

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

*and Consolidated*

1. Financial Results: Un-Audited Standalone Financial Results of the company for the First Quarter Ended 30<sup>th</sup> June, 2019.
2. Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the First Quarter Ended 30<sup>th</sup> June, 2019 by the Auditors.

This is for your Information and Necessary Records.

Thanking you  
For TRIMURTHI LIMITED

Arun Kumar Bhangadia  
Managing Director  
DIN: 00021024



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : [info@trimurthidrugs.com](mailto:info@trimurthidrugs.com)  
Website : [www.trimurthidrugs.com](http://www.trimurthidrugs.com)  
CIN No : L67120TG1994PLC018956

Date: 13.08.2019

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 13/08/2019 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Tuesday, the 13<sup>th</sup> Day of August, 2019 at Registered Office, have approved and taken on record the following:

1. The Board has considered and approved the minutes of the previous board meeting.
2. The Board has considered and approved the Unaudited Standalone Financial Results for the First Quarter ended 30<sup>th</sup> June, 2019 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.


*and Consolidated*

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.30 P.M. and Concluded at 04:30 P.M.

Request you to take same on records.

Thanking you  
For TRIMURTHI LIMITED



Arun Kumar Bhangadia

Managing Director  
DIN: 00021024

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : [info@trimurthidrugs.com](mailto:info@trimurthidrugs.com)  
Website : [www.trimurthidrugs.com](http://www.trimurthidrugs.com)  
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED  
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.  
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS  
FOR THE QUARTER ENDED 30TH JUNE 2019

PARTICULARS	QUARTER ENDED			
	30.06.2019 (UNAUDITED)	31.03.2019 (AUDITED)	30.06.2018 (UNAUDITED)	31.03.2019 (AUDITED)
<b>1. INCOME</b>				
INCOME FROM OPERATIONS	31.77	48.84	104.44	359.19
OTHER INCOME	4.09	11.14	0.86	13.23
<b>TOTAL INCOME</b>	<b>35.86</b>	<b>59.98</b>	<b>105.30</b>	<b>372.43</b>
<b>2. EXPENSES</b>				
PURCHASES	17.18	26.74	75.64	277.85
COST OF MATERIALS CONSUMED			-	
MANUFACTURING EXPENSES			-	
WORK IN PROGRESS AND STOCK IN TRADE	(1.86)	0.17	7.16	0.03
RENT	-	0.75	0.65	3.00
EMPLOYEE BENEFITS EXPENSE	5.49	8.07	6.22	32.72
FINANCE COSTS			-	
DEPRECIATION AND AMORTISATION EXPENSES	2.67	3.34	3.02	12.15
OTHER EXPENSES	3.67	6.70	11.74	28.39
<b>TOTAL EXPENSES</b>	<b>32.08</b>	<b>45.77</b>	<b>104.44</b>	<b>353.34</b>
<b>3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE EXCEPTIONAL ITEMS (1-2)</b>	<b>3.78</b>	<b>14.21</b>	<b>0.87</b>	<b>19.08</b>
<b>4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS</b>				
<b>5. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)</b>	<b>3.78</b>	<b>14.21</b>	<b>0.87</b>	<b>19.08</b>
<b>6. TAX EXPENSES</b>				
-CURRENT TAX	1.07	3.52	(2.50)	(5.92)
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	1.10	3.78	0.29	4.49
-DEFERRED TAX (NET)	(0.02)	(0.26)	(2.75)	(10.40)
<b>7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)</b>	<b>2.71</b>	<b>10.69</b>	<b>3.37</b>	<b>25.00</b>
<b>8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS</b>				
<b>9. TAX EXPENSES FOR DISCONTINUED OPERATIONS</b>				
<b>10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)</b>				
<b>11. PROFIT/(LOSS) FOR THE PERIOD (7+10)</b>	<b>2.71</b>	<b>10.69</b>	<b>3.37</b>	<b>25.00</b>
<b>12. OTHER COMPREHENSIVE INCOME</b>				
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS				
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS				
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS				
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	(1.90)	3.92	(8.57)	(6.20)
<b>13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)</b>	<b>0.81</b>	<b>14.61</b>	<b>(1.20)</b>	<b>18.80</b>
<b>14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION):</b>				
(i) BASIC	0.03	0.13	0.04	0.31
(ii) DILUTED	0.03	0.13	0.04	0.31
<b>15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION):</b>				
(i) BASIC	-	-	-	-
(ii) DILUTED	-	-	-	-
<b>16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION):</b>				
(i) BASIC	0.03	0.13	0.04	0.31
(ii) DILUTED	0.03	0.13	0.04	0.31

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S, INDIA. | Tel: 040 24757370  
Email : [info@trimurthidrugs.com](mailto:info@trimurthidrugs.com)  
Website : [www.trimurthidrugs.com](http://www.trimurthidrugs.com)  
CIN No : L67120TG1994PLC018956



## TRIMURTHI LIMITED



ANNUAL REPORT  
FOR THE FINANCIAL YEAR  
2018-19  
Trimurthi Limited  
REGD. NO. 102014  
DIN: 0757370  
CIN: 167120TG1994PLC018956

1. Notes  
2. The above standardised results have been prepared in accordance with the recognition and measurement principles used under and due to the fact  
3. ASAE interim financial reporting presented under Section 133 of the Companies Act, 2013 read with the relevant rules  
4. The audit committee of the Board of Directors of the Company held on  
5. Previous period figures have been regrouped, wherever necessary, for the purpose of comparison  
6. The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors held on  
7. 13th August 2019.  
8. The above standardised results have been prepared in accordance with the recognition and measurement principles used under and due to the fact  
9. ASAE interim financial reporting principles generally accepted in India.

PARTICULARS		QUARTER ENDING	YEAR ENDING	Segment Reporting
		30/06/2019	31/03/2019	30/06/2018
1. Segment Revenue				
1.1. Financial Services		12.88	12.76	16.98
1.2. Financial Services		12.88	12.76	16.98
1.3. Financial Services		12.88	12.76	16.98
1.4. Financial Services		12.88	12.76	16.98
1.5. Financial Services		12.88	12.76	16.98
1.6. Financial Services		12.88	12.76	16.98
1.7. Financial Services		12.88	12.76	16.98
1.8. Financial Services		12.88	12.76	16.98
1.9. Financial Services		12.88	12.76	16.98
1.10. Financial Services		12.88	12.76	16.98
1.11. Financial Services		12.88	12.76	16.98
1.12. Financial Services		12.88	12.76	16.98
1.13. Financial Services		12.88	12.76	16.98
1.14. Financial Services		12.88	12.76	16.98
1.15. Financial Services		12.88	12.76	16.98
1.16. Financial Services		12.88	12.76	16.98
1.17. Financial Services		12.88	12.76	16.98
1.18. Financial Services		12.88	12.76	16.98
1.19. Financial Services		12.88	12.76	16.98
1.20. Financial Services		12.88	12.76	16.98
1.21. Financial Services		12.88	12.76	16.98
1.22. Financial Services		12.88	12.76	16.98
1.23. Financial Services		12.88	12.76	16.98
1.24. Financial Services		12.88	12.76	16.98
1.25. Financial Services		12.88	12.76	16.98
1.26. Financial Services		12.88	12.76	16.98
1.27. Financial Services		12.88	12.76	16.98
1.28. Financial Services		12.88	12.76	16.98
1.29. Financial Services		12.88	12.76	16.98
1.30. Financial Services		12.88	12.76	16.98
1.31. Financial Services		12.88	12.76	16.98
1.32. Financial Services		12.88	12.76	16.98
1.33. Financial Services		12.88	12.76	16.98
1.34. Financial Services		12.88	12.76	16.98
1.35. Financial Services		12.88	12.76	16.98
1.36. Financial Services		12.88	12.76	16.98
1.37. Financial Services		12.88	12.76	16.98
1.38. Financial Services		12.88	12.76	16.98
1.39. Financial Services		12.88	12.76	16.98
1.40. Financial Services		12.88	12.76	16.98
1.41. Financial Services		12.88	12.76	16.98
1.42. Financial Services		12.88	12.76	16.98
1.43. Financial Services		12.88	12.76	16.98
1.44. Financial Services		12.88	12.76	16.98
1.45. Financial Services		12.88	12.76	16.98
1.46. Financial Services		12.88	12.76	16.98
1.47. Financial Services		12.88	12.76	16.98
1.48. Financial Services		12.88	12.76	16.98
1.49. Financial Services		12.88	12.76	16.98
1.50. Financial Services		12.88	12.76	16.98
1.51. Financial Services		12.88	12.76	16.98
1.52. Financial Services		12.88	12.76	16.98
1.53. Financial Services		12.88	12.76	16.98
1.54. Financial Services		12.88	12.76	16.98
1.55. Financial Services		12.88	12.76	16.98
1.56. Financial Services		12.88	12.76	16.98
1.57. Financial Services		12.88	12.76	16.98
1.58. Financial Services		12.88	12.76	16.98
1.59. Financial Services		12.88	12.76	16.98
1.60. Financial Services		12.88	12.76	16.98
1.61. Financial Services		12.88	12.76	16.98
1.62. Financial Services		12.88	12.76	16.98
1.63. Financial Services		12.88	12.76	16.98
1.64. Financial Services		12.88	12.76	16.98
1.65. Financial Services		12.88	12.76	16.98
1.66. Financial Services		12.88	12.76	16.98
1.67. Financial Services		12.88	12.76	16.98
1.68. Financial Services		12.88	12.76	16.98
1.69. Financial Services		12.88	12.76	16.98
1.70. Financial Services		12.88	12.76	16.98
1.71. Financial Services		12.88	12.76	16.98
1.72. Financial Services		12.88	12.76	16.98
1.73. Financial Services		12.88	12.76	16.98
1.74. Financial Services		12.88	12.76	16.98
1.75. Financial Services		12.88	12.76	16.98
1.76. Financial Services		12.88	12.76	16.98
1.77. Financial Services		12.88	12.76	16.98
1.78. Financial Services		12.88	12.76	16.98
1.79. Financial Services		12.88	12.76	16.98
1.80. Financial Services		12.88	12.76	16.98
1.81. Financial Services		12.88	12.76	16.98
1.82. Financial Services		12.88	12.76	16.98
1.83. Financial Services		12.88	12.76	16.98
1.84. Financial Services		12.88	12.76	16.98
1.85. Financial Services		12.88	12.76	16.98
1.86. Financial Services		12.88	12.76	16.98
1.87. Financial Services		12.88	12.76	16.98
1.88. Financial Services		12.88	12.76	16.98
1.89. Financial Services		12.88	12.76	16.98
1.90. Financial Services		12.88	12.76	16.98
1.91. Financial Services		12.88	12.76	16.98
1.92. Financial Services		12.88	12.76	16.98
1.93. Financial Services		12.88	12.76	16.98
1.94. Financial Services		12.88	12.76	16.98
1.95. Financial Services		12.88	12.76	16.98
1.96. Financial Services		12.88	12.76	16.98
1.97. Financial Services		12.88	12.76	16.98
1.98. Financial Services		12.88	12.76	16.98
1.99. Financial Services		12.88	12.76	16.98
1.100. Financial Services		12.88	12.76	16.98
1.101. Financial Services		12.88	12.76	16.98
1.102. Financial Services		12.88	12.76	16.98
1.103. Financial Services		12.88	12.76	16.98
1.104. Financial Services		12.88	12.76	16.98
1.105. Financial Services		12.88	12.76	16.98
1.106. Financial Services		12.88	12.76	16.98
1.107. Financial Services		12.88	12.76	16.98
1.108. Financial Services		12.88	12.76	16.98
1.109. Financial Services		12.88	12.76	16.98
1.110. Financial Services		12.88	12.76	16.98
1.111. Financial Services		12.88	12.76	16.98
1.112. Financial Services		12.88	12.76	16.98
1.113. Financial Services		12.88	12.76	16.98
1.114. Financial Services		12.88	12.76	16.98
1.115. Financial Services		12.88	12.76	16.98
1.116. Financial Services		12.88	12.76	16.98
1.117. Financial Services		12.88	12.76	16.98
1.118. Financial Services		12.88	12.76	16.98
1.119. Financial Services		12.88	12.76	16.98
1.120. Financial Services		12.88	12.76	16.98
1.121. Financial Services		12.88	12.76	16.98
1.122. Financial Services		12.88	12.76	16.98
1.123. Financial Services		12.88	12.76	16.98
1.124. Financial Services		12.88	12.76	16.98
1.125. Financial Services		12.88	12.76	16.98
1.126. Financial Services		12.88	12.76	16.98
1.127. Financial Services		12.88	12.76	16.98
1.128. Financial Services		12.88	12.76	16.98
1.129. Financial Services		12.88	12.76	16.98
1.130. Financial Services		12.88	12.76	16.98
1.131. Financial Services		12.88	12.76	16.98
1.132. Financial Services		12.88	12.76	16.98
1.133. Financial Services		12.88	12.76	16.98
1.134. Financial Services		12.88	12.76	16.98
1.135. Financial Services		12.88	12.76	16.98
1.136. Financial Services		12.88	12.76	16.98
1.137. Financial Services		12.88	12.76	16.98
1.138. Financial Services		12.88	12.76	16.98
1.139. Financial Services		12.88	12.76	16.98
1.140. Financial Services		12.88	12.76	16.98
1.141. Financial Services		12.88	12.76	16.98
1.142. Financial Services		12.88	12.76	16.98
1.143. Financial Services		12.88	12.76	16.98
1.144. Financial Services		12.88	12.76	16.98
1.145. Financial Services		12.88	12.76	16.98
1.146. Financial Services		12.88	12.76	16.98
1.147. Financial Services		12.88	12.76	16.98
1.148. Financial Services		12.88	12.76	16.98
1.149. Financial Services		12.88	12.76	16.98
1.150. Financial Services		12.88	12.76	16.98
1.151. Financial Services		12.88	12.76	16.98
1.152. Financial Services		12.88	12.76	16.98
1.153. Financial Services		12.88	12.76	16.98
1.154. Financial Services		12.88	12.76	16.98
1.155. Financial Services		12.88	12.76	16.98
1.156. Financial Services		12.88	12.76	16.98
1.157. Financial Services		12.88	12.76	16.98
1.158. Financial Services		12.88	12.76	16.98
1.159. Financial Services		12.88	12.76	16.98
1.160. Financial Services		12.88	12.76	16.98
1.161. Financial Services		12.88	12.76	16.98
1.162. Financial Services		12.88	12.76	16.98
1.163. Financial Services		12.88	12.76	16.98
1.164. Financial Services		12.88	12.76	16.98
1.165. Financial Services		12.88	12.76	16.98
1.166. Financial Services		12.88	12.76	16.98
1.167. Financial Services		12.88	12.76	16.98
1.168. Financial Services		12.88	12.76	16.98
1.169. Financial Services		12.88	12.76	16.98
1.170. Financial Services		12.88	12.76	16.98
1.171. Financial Services		12.88	12.76	16.98
1.172. Financial Services		12.88	12.76	16.98
1.173. Financial Services		12.88	12.76	16.98
1.174. Financial Services		12.88	12.76	16.98
1.175. Financial Services		12.88	12.76	16.98
1.176. Financial Services		12.88	12.76	16.98
1.177. Financial Services		12.88	12.76	16.98
1.178. Financial Services		12.88	12.76	16.98
1.179. Financial Services		12.88	12.76	16.98
1.180. Financial Services		12.88	12.76	16.98
1.181. Financial Services		12.88	12.76	16.98
1.182. Financial Services		12.88	12.76	16.98
1.183. Financial Services		12.88	12.76	16.98
1.184. Financial Services		12.88	12.76	16.98
1.185. Financial Services		12.88	12.76	16.98
1.186. Financial Services		12.88	12.76	16.98
1.187. Financial Services		12.88	12.76	16.98
1.188. Financial Services		12.88	12.76	16.98
1.189. Financial Services		12.88	12.76	16.98
1.190. Financial Services		12.88	12.76	16.98
1.191. Financial Services		12.88	12.76	16.98
1.192. Financial Services		12.88	12.76	16.98
1.193. Financial Services		12.88	12.76	16.98
1.194. Financial Services		12.88	12.76	16.98
1.195. Financial Services		12.88	12.76	16.98
1.196. Financial Services		12.88	12.76	16.98
1.197. Financial Services		12.88	12.76	16.98
1.198. Financial Services		12.88	12.76	16.98
1.199. Financial Services		12.88	12.76	16.98
1.200. Financial Services		12.88	12.76	16.98
1.201. Financial Services		1		



**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : [www.pmurali.com](http://www.pmurali.com)

**Limited Review Report- Standalone Financial Results**

To

The Board of Directors,  
Trimurthi Limited (Formerly known as Trimurthi Drugs & Pharmaceuticals limited),  
Hyderabad.

1. We have reviewed the accompanying statement of unaudited standalone financial results of Trimurthi Limited ("the Company") for the quarter ended 30<sup>th</sup> June, 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD1/ 44/2019 dated March 29, 2019
2. The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 13<sup>th</sup> August 2019. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

- Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.

Chartered Accountants

FRN: 007257S



A.KrishnaRao

Partner

M.No. 020085

UDIN: 19020085AAAAG1R8197

Place: Hyderabad

Date: 13-08-2019

**TRIMURTHI LIMITED**  
 SCHEDULE III OF THE COMPANIES ACT 2013  
 CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019



**TRIMURTHI**  
 GROUP

PART-I

Particulars	Quarter Ended			Year Ended
	30-06-2019	31-03-2019	30-06-2018	31-03-2019
	Unaudited	Audited	Unaudited	Audited
<b>I. Income From Operations</b>				
Net Sales / Income from Operations	243.68	255.39	336.01	1,045.92
Other Income	4.24	34.93	1.06	37.73
<b>II. Total Income</b>	<b>247.92</b>	<b>290.32</b>	<b>337.07</b>	<b>1,083.65</b>
<b>III. Expenses</b>				
a. Consumption of Raw Material	31.47	28.81	41.51	154.21
b. Purchase of Traded Goods/Shares	137.91	146.71	226.43	594.28
c. (Increase)/Decrease in stock in trade and work in Progress	(9.68)	19.23	(5.24)	1.95
d. Manufacturing Expenses	39.22	36.86	36.05	153.86
e. Employee benefits expense	22.24	22.95	24.04	98.62
f. Rent	1.50	1.95	1.85	7.80
g. Finance Cost	3.70	18.36	2.98	12.97
h. Depreciation	5.33	5.77	5.12	21.25
i. Other Expenditure	14.59	10.37	17.99	51.12
<b>Total</b>	<b>246.30</b>	<b>276.00</b>	<b>350.72</b>	<b>1,096.05</b>
<b>IV. Profit/ (Loss) before Exceptional and Tax (II-III)</b>	<b>1.63</b>	<b>14.32</b>	<b>(13.65)</b>	<b>(12.40)</b>
<b>V. Exceptional Items/Prior Period Items</b>				
<b>VI. Profit/ (Loss) before tax (IV-V)</b>	<b>1.63</b>	<b>14.32</b>	<b>(13.65)</b>	<b>(12.40)</b>
<b>VII. Tax expense:</b>	<b>2.65</b>	<b>5.42</b>	<b>(2.29)</b>	<b>2.38</b>
(1) Current tax	2.15	5.09	0.34	10.51
(2) Deferred tax	0.50	0.34	(2.62)	(8.12)
<b>VIII. Net Profit/ (Loss) for the period from continuing operations (VI-VII)</b>	<b>(1.03)</b>	<b>8.89</b>	<b>(11.36)</b>	<b>(14.79)</b>
<b>IX. Profit/(loss) from discontinued operations</b>				
<b>X. Tax expenses of discontinued operations</b>				
<b>XI. Profit/(loss) from Discontinued operations (after tax) (IX-X)</b>				
<b>XII. Profit/(loss) for the period (VIII+XI)</b>	<b>(1.03)</b>	<b>8.89</b>	<b>(11.36)</b>	<b>(14.79)</b>
<b>XIII. Other Comprehensive Income</b>				
A. (i) Items that will not be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B. (i) Items that will be reclassified to profit or loss	(1.90)	9.76	(4.61)	(0.43)
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>XIV. Total Comprehensive Income for the period (XII+XIII)Comprising Profit (Loss) and Other comprehensive Income for the period )</b>	<b>(2.93)</b>	<b>18.65</b>	<b>(15.96)</b>	<b>(15.21)</b>
<b>XV. Minority Interest</b>	<b>1.12</b>	<b>3.91</b>	<b>1.96</b>	<b>9.40</b>
<b>XVI. Total Comprehensive Income for the period after Minority Interest (XIV-XV)</b>	<b>(4.05)</b>	<b>11.74</b>	<b>(17.92)</b>	<b>(24.62)</b>
<b>XVII. Earnings per equity share (for continuing operation):</b>				
(1) Basic	(0.03)	0.06	(0.16)	(0.30)
(2) Diluted	(0.03)	0.06	(0.16)	(0.30)
<b>XVIII. Earnings per equity share (for discontinuing operation):</b>				
(1) Basic	-	-	-	-
(2) Diluted	-	-	-	-
<b>XIX. Earnings per equity share (for discontinuing &amp; continuing operation):</b>				
(1) Basic	(0.03)	0.06	(0.16)	(0.30)
(2) Diluted	(0.03)	0.06	(0.16)	(0.30)

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)

4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email : info@trimurthidrugs.com

Website : www.trimurthidrugs.com

CIN No : L67120TG1994PLC018956



Dated : 15/07/2019

**TRIMURTHI LIMITED**  
**SCHEDULE III OF THE COMPANIES ACT 2013**  
**PART-II**



**TRIMURTHI**

Particulars	Quarter Ended				Year Ended
	30-06-2019 Unaudited	31-03-2019 Audited	30-06-2018 Unaudited	31-03-2019 Audited	
<b>A. Particulars Of Share Holding</b>					
1. Public Share Holding					
- Number of Shares	29,00,600	29,00,600	29,00,600	29,00,600	
- Percentage of shareholding	35.81%	35.81%	35.81%	35.81%	
2. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	-	-	-	-	
- Percentage of Shares (of the shareholding of promoter and promoter group)	-	-	-	-	
- Percentage of Shares (of the total share capital of the company)	-	-	-	-	
b. Non encumbered					
- No of Equity Shares	51,99,400	51,99,400	51,99,400	51,99,400	
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	
- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	

Particulars	3 Months Ended ( 30/06/2019)
<b>B. Investor Complaints</b>	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

**Segment Reporting**

Particulars	Quarter Ended		Year Ended	
	30-06-2019 Unaudited	31-03-2019 Audited	30-06-2018 Unaudited	31-03-2019 Audited
<b>1. Segment Revenue</b>				
a. Pharma Business	130.90	182.68	156.12	663.56
b. Financial Services	12.88	12.83	16.98	57.78
c. Investments	3.85	11.14	-	12.99
d. Foods	81.16	73.69	77.05	318.51
e. Trading in Shares	19.12	9.98	11.27	30.81
<b>Total</b>	<b>247.92</b>	<b>290.32</b>	<b>261.43</b>	<b>1,083.65</b>
<b>Less: Inter Segment Revenue</b>	-	-	-	-
<b>Net Sales/Income From Operations</b>	<b>247.92</b>	<b>290.32</b>	<b>261.43</b>	<b>1,083.65</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>				
a. Pharma Business	3.95	5.02	5.15	23.20
b. Financial Services	6.18	5.56	13.64	32.62
c. Investments	3.85	11.14	-	12.99
d. Foods	(6.10)	(12.20)	(34.21)	(95.19)
e. Trading in Shares	(6.25)	4.81	1.78	13.97
<b>Total</b>	<b>1.63</b>	<b>14.32</b>	<b>(13.65)</b>	<b>(12.40)</b>
<b>Less:</b>				
i. Interest	-	-	-	-
ii. Other Un-allocable expenses net off	-	-	-	-
iii. Un-allocable Income	-	-	-	-
<b>Total Profit Before Tax</b>	<b>1.63</b>	<b>14.32</b>	<b>(13.65)</b>	<b>(12.40)</b>
<b>3. Capital Employed</b>				
a. Pharma Business	86.01	83.41	83.42	85.41
b. Financial Services	456.43	453.22	442.65	453.22
c. Investments	37.72	49.14	80.15	49.14
d. Foods	192.02	190.67	186.22	190.67
e. Trading in Shares	315.84	313.62	306.30	313.62
<b>Total</b>	<b>1,068.01</b>	<b>1,092.06</b>	<b>1,098.75</b>	<b>1,092.06</b>

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S, INDIA, | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



Notes:

- 1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 2 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th August, 2019.
- 3 The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 30th September, 2017. The Ind-AS Complaint figures for the Corresponding previous Quarter ended 30th September, 2016 have not been subject to review or audit, however the Company's management has exercised
- 4 The results are also available on the website of the Company

Place : Hyderabad

Date : 13-08-2019

For TRIMURTHI LIMITED



## TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : [info@trimurthidrugs.com](mailto:info@trimurthidrugs.com)  
Website : [www.trimurthidrugs.com](http://www.trimurthidrugs.com)  
CIN No : L67120TG1994PLC018956



**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

**Limited Review Report – Consolidated Financial Results**

To

The Board of Directors,  
Trimurthi Limited (Formerly known as Trimurthi Drugs & Pharmaceuticals limited),  
Hyderabad.

1. We have reviewed the accompanying statement of unaudited consolidated financial results ("the statement") of Trimurthi Limited Group comprising Trimurthi Limited ("the Parent") and its subsidiaries (together referred to as 'the Group'), for the quarter ended 30<sup>th</sup> June, 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD1/ 44/2019 dated March 29, 2019.
2. The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 13th August 2019. Our responsibility is to express a conclusion on "the Statement" based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

4. The consolidated unaudited results include the results of the following entities:

- (a) Trimurthi Foods Limited
- (b) Trimurthi Pharmaceuticals India Private Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S

  
A. Krishna Rao  
Partner  
M.No. 020085  
UDIN: 19020085AAAAG1S7025



Place: Hyderabad  
Date: 13-08-2019